Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 3, 2015, Pages 531-541

  Velstra, Berit ^a   Vonk, Marieke A ^a   Bonsing, Bert A ^a   Mertens, Bart J ^a   Nicolardi, Simone ^a   Huijbers, Anouck ^a   Vasen, Hans ^a   Deelder, André M ^a   Mesker, Wilma E ^a   van der Burgt, Yuri E M ^a   Tollenaar, Rob A E M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker signature; Clinical decision making; MALDI TOF; Proteomics; Screening

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN; PEPTIDE FRAGMENT; PLASMA PROTEIN; TUMOR MARKER;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DISCRIMINANT ANALYSIS; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PANCREAS CANCER; PRIORITY JOURNAL; SERUM; SMOKING; SOLID PHASE EXTRACTION; ADENOCARCINOMA; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; FOLLOW UP; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PROCEDURES; PROGNOSIS; PROTEOMICS; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BLOOD PROTEINS; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; DIAGNOSTIC IMAGING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREAS; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC; YOUNG ADULT;

EID: 84925538145     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1812-2     Document Type: Article

References (43)

1. Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422:198–207
2. Albrethsen J (2007) Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem 53:852–858
3. Bipat S, Phoa SS, van Delden OM, Bossuyt PM, Gouma DJ, Lameris JS, Stoker J (2005) Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 29:438–445
4. Bladergroen MR, Derks RJ, Nicolardi S, de Visser B, van Berloo S, van der Burgt YE, Deelder AM (2012) Standardized and automated solid-phase extraction procedures for high-throughput proteomics of body fluids. J Proteomics 77:144–153
5. Cecconi D, Palmieri M, Donadelli M (2011) Proteomics in pancreatic cancer research. Proteomics 11:816–828
6. Chen JH, Ni RZ, Xiao MB, Guo JG, Zhou JW (2009) Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue. Hepatobiliary Pancreat Dis Int 8:193–200
7. de Noo ME, Tollenaar RA, Ozalp A, Kuppen PJ, Bladergroen MR, Eilers PH, Deelder AM (2005) Reliability of human serum protein profiles generated with C8 magnetic beads assisted MALDI-TOF mass spectrometry. Anal Chem 77:7232–7241
8. Deng R, Lu Z, Chen Y, Zhou L, Lu X (2007) Plasma proteomic analysis of pancreatic cancer by 2-dimensional gel electrophoresis. Pancreas 34:310–317
9. Dewitt J, Devereaux BM, Lehman GA, Sherman S, Imperiale TF (2006) Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. Clin Gastroenterol Hepatol 4:717–725
10. Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, Vorderwulbecke S, Bogumil R, Buchler MW, Friess H (2007) Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34:205–214
11. Ghatnekar O, Andersson R, Svensson M, Persson U, Ringdahl U, Zeilon P, Borrebaeck CA (2013) Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature. Int J Cancer 133:2392–2397
12. Gianazza E, Chinello C, Mainini V, Cazzaniga M, Squeo V, Albo G, Signorini S, Di Pierro SS, Ferrero S, Nicolardi S, van der Burgt YEM, Deelder AM, Magni F (2012) Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors. J Proteomics 5:125–140
13. Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33:266–270
14. Hansson GC, Zopf D (1985) Biosynthesis of the cancer-associated sialyl-Lea antigen. J Biol Chem 260:9388–9392
15. Honda K, Hayashida Y, Umaki T, Okusaka T, Kosuge T, Kikuchi S, Endo M, Tsuchida A, Aoki T, Itoi T, Moriyasu F, Hirohashi S, Yamada T (2005) Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res 65:10613–10622
16. Hortin GL (2006) The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 52:1223–1237
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
18. Jimenez CR, El FZ, Knol JC, Hoekman K, Kruyt FA, Giaccone G, Smit AB, Li KW (2007) Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. Proteomics Clin Appl 1:598–604
19. Kakisaka T, Kondo T, Okano T, Fujii K, Honda K, Endo M, Tsuchida A, Aoki T, Itoi T, Moriyasu F, Yamada T, Kato H, Nishimura T, Todo S, Hirohashi S (2007) Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci 852:257–267
20. Kojima K, Asmellash S, Klug CA, Grizzle WE, Mobley JA, Christein JD (2008) Applying proteomic-based biomarker tools for the accurate diagnosis of pancreatic cancer. J Gastrointest Surg 12:1683–1690
21. Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ, Abbruzzese JL, Kobayashi R (2005) Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 11:1110–1118
22. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M (2004) Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10:860–868
23. Liu D, Cao L, Yu J, Que R, Jiang W, Zhou Y, Zhu L (2009) Diagnosis of pancreatic adenocarcinoma using protein chip technology. Pancreatology 9:127–135
24. Lynch SM, Vrieling A, Lubin JH, Kraft P, Mendelsohn JB, Hartge P, Canzian F, Steplowski E, Arslan AA, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Petersen G, Zheng W, Albanes D, Amundadottir L, Bingham SA, Boffetta P, Boutron-Ruault MC, Chanock SJ, Clipp S, Hoover RN, Jacobs K, Johnson KC, Kooperberg C, Luo J, Messina C, Palli D, Patel AV, Riboli E, Shu XO, Rodriguez SL, Thomas G, Tjonneland A, Tobias GS, Tong E, Trichopoulos D, Virtamo J, Ye W, Yu K, Zeleniuch-Jacquette A, Bueno-de-Mesquita HB, Stolzenberg-Solomon RZ (2009) Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 170:403–413
25. Mertens BJ, de Noo ME, Tollenaar RA, Deelder AM (2006) Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm. J Comput Biol 13:1591–1605
26. Micames C, Jowell PS, White R, Paulson E, Nelson R, Morse M, Hurwitz H, Pappas T, Tyler D, McGrath K (2003) Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc 58:690–695
27. Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidandel L, Fadi E, Zambon CF, Bozzato D, Moz S, Seraglia R, Pedrazzoli S, Plebani M (2009) Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. Clin Chem Lab Med 47:713–723
28. Nicolardi S, Palmblad M, Dalebout H, Bladergroen M, Tollenaar RA, Deelder AM, van der Burgt YE (2010) Quality control based on isotopic distributions for high-throughput MALDI-TOF and MALDI-FTICR serum peptide profiling. J Am Soc Mass Spectrom 21:1515–1525
29. Nilsson T, Mann M, Aebersold R, Yates JR III, Bairoch A, Bergeron JJ (2010) Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods 7:681–685
30. Orlando LA, Kulasingam SL, Matchar DB (2004) Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. Aliment Pharmacol Ther 20:1063–1070
31. Pawa N, Wright JM, Arulampalam TH (2010) Mass spectrometry based proteomic profiling for pancreatic cancer. JOP 11:423–426
32. Sener SF, Fremgen A, Menck HR, Winchester DP (1999) Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189:1–7
33. Shen Y, Tolic N, Liu T, Zhao R, Petritis BO, Gritsenko MA, Camp DG, Moore RJ, Purvine SO, Esteva FJ, Smith RD (2010) Blood peptidome-degradome profile of breast cancer. PLoS ONE 5:e13133
34. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236
35. Sun ZL, Zhu Y, Wang FQ, Chen R, Peng T, Fan ZN, Xu ZK, Miao Y (2007) Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim Biophys Acta 1774:764–771
36. Takadate T, Onogawa T, Fukuda T, Motoi F, Suzuki T, Fujii K, Kihara M, Mikami S, Bando Y, Maeda S, Ishida K, Minowa T, Hanagata N, Ohtsuka H, Katayose Y, Egawa S, Nishimura T, Unno M (2013) Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. Int J Cancer 132:1368–1382
37. Tiss A, Smith C, Menon U, Jacobs I, Timms JF, Cramer R (2010) A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. Proteomics 10:3388–3392
38. Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87:809–811
39. Vasen HF, Wasser M, van MA, Tollenaar RA, Konstantinovski M, Gruis NA, Bergman W, Hes FJ, Hommes DW, Offerhaus GJ, Morreau H, Bonsing BA, De Vostot Nederveen Cappel WH (2011) Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140:850–856
40. Velstra B, van der Burgt YE, Mertens BJ, Mesker WE, Deelder AM, Tollenaar RA (2012) Improved classification of breast cancer peptide and protein profiles by combining two serum workup procedures. J Cancer Res Clin Oncol 138:1983–1992
41. Velstra B, Bonsing BA, Mertens BJ, van der Burgt YE, Huijbers A, Vasen H, Mesker WE, Deelder AM, Tollenaar RA (2013) Detection of pancreatic cancer using serum protein profiling. HPB (Oxford) 15:602–610
42. Yu KH, Rustgi AK, Blair IA (2005) Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 4:1742–1751
43. Zapico-Muniz E, Farre-Viladrich A, Rico-Santana N, Gonzalez-Sastre F, Mora-Brugues J (2010) Standardized peptidome profiling of human serum for the detection of pancreatic cancer. Pancreas 39:1293–1298